Boudes Pol F 4
4 · GALECTIN THERAPEUTICS INC · Filed Feb 7, 2024
Insider Transaction Report
Form 4
Boudes Pol F
Chief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2024-01-24+65,000→ 65,000 totalExercise: $1.11Exp: 2034-01-24→ Common Stock (65,000 underlying) - Award
Restricted Stock Unit
2024-01-24+40,000→ 40,000 total→ Common Stock (40,000 underlying)
Footnotes (4)
- [F1]The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
- [F2]The options vest as follows: 25% on each of June 30, 2023; December 31, 2023; June 30, 2024; and December 31, 2024.
- [F3]The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.
- [F4]Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.